1) Zantac (ranitidine) is an antisecretory drug that competitively and reversibly inhibits histamine action at H2-receptor sites on parietal cells, thus blocking gastric acid secretion.
2) It is used for the short-term treatment of active duodenal ulcer, maintenance therapy for duodenal ulcer patients after healing of acute ulcer, treatment of gastroesophageal reflux disease, short-term treatment of active, benign gastric ulcer, and treatment of pathologic GI hypersecretory conditions.
3) Potential adverse effects include headache, malaise, dizziness, somnolence, insomnia, vertigo, mental confusion, agitation, depression
1) Zantac (ranitidine) is an antisecretory drug that competitively and reversibly inhibits histamine action at H2-receptor sites on parietal cells, thus blocking gastric acid secretion.
2) It is used for the short-term treatment of active duodenal ulcer, maintenance therapy for duodenal ulcer patients after healing of acute ulcer, treatment of gastroesophageal reflux disease, short-term treatment of active, benign gastric ulcer, and treatment of pathologic GI hypersecretory conditions.
3) Potential adverse effects include headache, malaise, dizziness, somnolence, insomnia, vertigo, mental confusion, agitation, depression
1) Zantac (ranitidine) is an antisecretory drug that competitively and reversibly inhibits histamine action at H2-receptor sites on parietal cells, thus blocking gastric acid secretion.
2) It is used for the short-term treatment of active duodenal ulcer, maintenance therapy for duodenal ulcer patients after healing of acute ulcer, treatment of gastroesophageal reflux disease, short-term treatment of active, benign gastric ulcer, and treatment of pathologic GI hypersecretory conditions.
3) Potential adverse effects include headache, malaise, dizziness, somnolence, insomnia, vertigo, mental confusion, agitation, depression
1) Zantac (ranitidine) is an antisecretory drug that competitively and reversibly inhibits histamine action at H2-receptor sites on parietal cells, thus blocking gastric acid secretion.
2) It is used for the short-term treatment of active duodenal ulcer, maintenance therapy for duodenal ulcer patients after healing of acute ulcer, treatment of gastroesophageal reflux disease, short-term treatment of active, benign gastric ulcer, and treatment of pathologic GI hypersecretory conditions.
3) Potential adverse effects include headache, malaise, dizziness, somnolence, insomnia, vertigo, mental confusion, agitation, depression
Download as DOCX, PDF, TXT or read online from Scribd
Download as docx, pdf, or txt
You are on page 1of 2
Dose,
Name and Frequency,
Mechanism Classification of Route, Duration Indication Contraindication Adverse Effects Nursing Responsibility of Action Drug of Administration Brand Name: Dose: Potent anti- Short-term Hypersensitivity CNS: Headache, Potential toxicity results Zantac 50mg ulcer treatment of to malaise, dizziness, from decreased clearance drug that active duodenal ranitidine; acute somnolence, (elimination) and therefore Generic Name: Frequency: competitively ulcer. porphyria; OTC insomnia, vertigo, prolonged action; greatest Ranitidine q8 and Maintenance administration in mental confusion, in the older adult patients reversibly therapy for children agitation, or those with hepatic or Drug Class: Route: inhibits duodenal ulcer <12 y. depression, renal dysfunction. Antisecretory IV histamine patient after hallucinations in action healing of acute older adults. at H2- ulcer; treatment CV: receptor of Bradycardia (with sites on gastroesophagea rapid IV push). parietal l reflux disease; GI: Constipation, cells, thus short-term nausea, abdominal blocking treatment of pain, diarrhea. gastric active, benign Skin: Rash. acid gastric ulcer; Hematologic: secretion. treatment of Reversible Indirectly pathologic GI decrease in WBC reduces hypersecretory count, pepsin conditions (e.g., thrombocytopenia. secretion Zollinger- Body as a Whole: but appears Ellison Hypersensitivity to syndrome, reactions, have minimal systemic anaphylaxis (rare). effect on mastocytosis, fasting and and postoperative postprandial hypersecretion); serum gastrin heartburn. concentration s or secretion of gastric intrinsic factor or mucus
Status and Clinical Experiences From The Challenge Trial - A Randomized Controlled Trial Investigating Virtual Reality-Based Therapy For Auditory Hallucinations